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Dopamine receptor stimulation causes vascular and neu•
rohumoral responses that may be beneficial in patients 
with heart failure. Oral inactivity, emesis and adre•
nergic-induced arrhythmias have limited the use of cur•
rently available compounds. Fenoldopam (SKF -82526-J) 
is anew, orally available, selective, dopamine-receptor 
agonist with potent renal vasodilating properties (six times 
that of dopamine) without positive inotropic or adren•
ergic activity. Drug efficacy was clinically evaluated in 
10 patients with heart failure after single oral doses of 
placebo and 50, 100 and 200 mg of medication. Placebo 
produced no changes. Peak efficacy was noted 30 min•
utes to 1 hour after the 200 mg dose with mean blood 
pressure decreasing from 96 ± 15 (mean ± SD) to 
83 ± 8 mm Hg (p < 0.05), pulmonary capillary wedge 
pressure decreasing from 23 ± 6 to 20 ± 8 mm Hg 
Early in the last decade, dopamine was introduced for the 
treatment of congestive heart failure (1). Hemodynamic ef•
fects observed with different concentrations of dopamine 
were attributed to the simultaneous activation of both alpha•
and beta-adrenergic receptors, as well as the stimulation of 
specific dopamine receptors (1,2). Recent research (3) has 
provided evidence that activation of these dopamine recep•
tors results in a variety of vascular and neurohumoral re•
sponses in the cardiovascular system. This has led to the 
development of newer compounds that selectively activate 
the dopamine receptors and have few, if any, other adrener•
gic sequellae and are orally effective (4). These properties 
make dopamine analogs a new and attractive therapeutic 
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(p < 0.05) and mean pulmonary artery pressure de•
creasing from 32 ± 9 to 29 ± 8 mm Hg (p < 0.05). 
Systemic vascular resistance decreased from 1,987 ± 
887 to 1,191 ± 559 dynes-s-cm-s (p < 0.05) with a sub•
sequent 55% increase in cardiac index from 2.2 ± 1.1 
to 3.1 ± 1.3 liters/min per m2 (p < 0.05). Heart rate 
and right atrial pressure did not change (p > 0.05). No 
emesis or new tachycardia was noted at any dose. Base•
line hemodynamics generally returned within 3 to 4 hours. 
Fenoldopam, therefore, is a short-acting, orally ef•
fective drug that decreases systemic vascular resistance 
and increases cardiac index in patients with heart failure 
and represents a new class of oral compounds that may 
be useful in treating such patients. 
(J Am Coil CardioI1985;6:792-6) 
option to employ during management of patients with 
congestive heart failure and those with disorders resulting 
in renal retention of salt and water. Dopamine itself, how•
ever, is only effective when given parenterally and may 
induce tachycardia and arrhythmias because of its adrenergic 
activity. 
Fenoldopam mesylate (SKF-82526-J) is a novel and po•
tent benzazepine derivative synthesized with the objective 
of obtaining enhanced selectivity for the activation of pe•
ripheral vascular dopaminel receptors (5). It is active both 
in the oral and intravenous formulations, a distinct advan•
tage over existing dopaminergic compounds, is six times as 
potent as dopamine in producing renal vasodilation and POS" 
sesses no adrenergic activity. This study was designed to 
evaluate, for the first time, the hemodynamic effects of 
fenoldopam in patients with congestive heart failure. 
Methods 
Patients. Using a protocol approved by the Baylor Col•
lege of Medicine Institutional Review Board for Human 
Research, we studied 10 patients with a congestive state 
caused by left ventricular dysfunction. Nine patients (seven 
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with idiopathic dilated cardiomyopathy and two with coro•
nary artery disease) had severe, chronic heart failure with 
New York Heart Association functional class III to IV symp•
toms and a mean (± SD) ejection fraction of 20 ± 8% 
(range 11 to 33). One patient had hypertensive heart disease 
and clinical features of heart failure. 
Study design. The study was random ordered, single 
blinded and placebo controlled. Diuretic drugs and vaso•
dilators were discontinued for more than 24 hours before 
hemodynamic study. All patients were maintained on a sta•
ble dose of digoxin. After obtaining informed consent, right 
heart catheterization was performed using a flow-directed, 
triple lumen, balloon-tipped thermodilution catheter in a 
standard fashion. The catheter was inserted 24 hours before 
the study. The mean right atrial, pUlmonary artery and pul•
monary capillary wedge pressures were measured. Cardiac 
output was obtained in triplicate by the thermodilution tech•
nique using a thermodilution computer with a variation of 
less than 10%. Arterial pressure was measured with a mer•
cury manometer and cuff over the brachial artery. Calculated 
hemodynamic indexes included: 
Systemic vascular resistance in dynes.s.cm- 5 : 
Mean arterial pressure - Right atrial pressure 
--------"-------"'----...!.....-- x 80; 
Cardiac output 
Mean blood pressure in mm Hg: 
([Systolic blood pressure - Diastolic blood pressure] x 0.33) 
+ Diastolic blood pressure; 
Cardiac index in liters/min per m2 : 
Cardiac output . 
Body surface area' 
Stroke volume index in mllm2 : 
Cardiac output/Heart rate 
Body surface area 
Left ventricular stroke work index in g-m/m2: 
Stroke volume index (Mean arterial pressure 
- Pulmonary wedge pressure) x 0.0136. 
The study was performed during a 4 day period in our 
cardiac care unit. On each study day, patients received a 
single dose of either placebo or 50, 100 or 200 mg of active 
drug in a random order. All patients had an overnight fast 
of more than 8 hours and oral intake was allowed approx•
imately 4 to 6 hours after the medication had been admin•
istered. Hemodynamic variables were obtained at baseline 
study and repeated 30 minutes and 1, 2, 3 and 4 hours after 
administering medication. 
Data analysis. The statistical analysis, comparing base•
line hemodynamic values obtained with placebo and the 
different medication doses, was performed using the non-
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parametric, paired value, Wilcoxon signed rank test. Results 
were deemed significant if the p value was less than 0.05. 
Results 
Hemodynamic results. All the hemodynamic measure•
ments for the group are summarized in Tables 1 and 2. 
Figure 1 presents the first 3 hours of data as the mean (± 
SEM) percent change from baseline measurement for heart 
rate, pulmonary capillary wedge pressure, systemic vascular 
resistance and cardiac index. 
Placebo dosing in each patient did not significantly change 
any of the measured or calculated variables. Heart rate and 
right atrial pressure were unaffected not only by placebo, 
but also by any dose of drug. 
The 50 mg dose caused no dramatic changes. There was 
a tendency for the mean blood pressure (Fig. 1), mean 
pulmonary capillary wedge pressure (Fig. 1) and systemic 
vascular resistance (Fig. 1) to decrease (decreases of 4, 3 
and 17% from baseline, respectively); only the decrease in 
systemic vascular resistance was significant (p < 0.05). 
The 50 mg dose caused no dramatic changes. There was 
a tendency for the mean blood pressure (Fig. 1), mean 
pulmonary capillary wedge pressure (Fig. 1) and systemic 
vascular resistance (Fig. I) to decrease (decreases of 4, 3 
utes, p < 0.01), systemic vascular resistance (a 35% de•
crease at 30 minutes, p < 0.01) and an increase in cardiac 
index (a 42% increase at 30 minutes, p < 0.01). 
The greatest responses were generally seen with the 200 
mg dose (Table 2). As with the 100 mg dose, per.I( effects 
after 200 mg of fenoldopam were noted early (between 30 
minutes and 1 hour) with significant changes persisting at 
approximately 2 hours. Cardiac and stroke volume indexes, 
increased significantly from 2.2 ± 1.1 to 3.1 ± 1.3 li•
ters/min per m2 and 25 ± 16 to 33 ± 15 mllm2 , respectively 
(mean ± SD, both P < 0.05). There were no significant 
changes in heart rate (94 ± 12 to 98 ± 11 beats/min) but 
there was a significant decrease in mean arterial blood pres•
sure from 96 ± 15 to 83 ± 8 mm Hg (p < 0.05). Systemic 
vascular resistance decreased significantly from 1,987 ± 
887 to 1,191 ± 559 dynes.s-cm- 5(p < 0.01). A slight 
decrease was observed in pUlmonary capillary wedge pres•
sure (23 ± 6 to 20 ± 8 mm Hg, p < 0.05) and mean 
pulmonary artery pressure (32 ± 9 to 29 ± 8 mm Hg, 
p < 0.05). 
Baseline hemodynamics returned 3 to 4 hours after ad•
ministering the medication. For the 100 mg dose, however, 
systemic vascular resistance did remain lower and cardiac 
index higher (both p < 0.05) at the 4 hour observation point 
(Table 2). 
Additional observations. No significant side effects were 
noted. One patient developed transient nausea with emesis 
I hour after receiving medication (200 mg dose) and this 
resolved spontaneously in 15 minutes. No new tachycardia 
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Table 1. Measured Hemodynamic Effects of Fenoldopam 
Variable Baseline 30 Minutes 
Heart rate (beats/min) 
Placebo 96 ± 19 97 ± 18 
50 mg 96 ± 16 98 ± 11 
100 mg 96 ± 11 96 ± 9 
200 mg 94 ± 12 96 ± 8 
Mean arterial pressure (mm Hg) 
Placebo 94 ± 14 95 ± 13 
50 mg 95 ± 16 91 ± 13 
100 mg 97 ± 14 87 ± 19* 
200 mg 96 ± 15 86 ± 12* 
Mean right arterial pressure (mm Hg) 
Placebo 14 ± 7 14 ± 7 
50 mg 13 ± 7 12 ± 7 
100mg 13 ± 6 13 ± 6 
200 mg 13 ± 7 13 ± 7 
Mean pulmonary artery pressure (mm Hg) 
Placebo 36 ± 12 36 ± 12 
50 mg 32 ± 12 32 ± 12 
100mg 33 ± 9 30 ± 9* 
200 mg 32 ± 9 29 ± 8* 
Mean pulmonary capillary wedge pressure 
Placebo 23 ± 7 25 ± 8 
50 mg 23 ± 7 23 ± 8 
100mg 23 ± 8 21 ± 8* 
200 mg 23 ± 6 20 ± 8* 
*p < 0.05. 
or acute rhythm disturbances were noted during bedside 
electrocardiographic monitoring while the drug was given. 
Discussion 
Fenoldopam description. Fenoldopam mesylate is a 
benzazepine derivative that appears to act primarily by stim•
ulation of the dopamine, receptors (6). It is orally effective, 
more receptor specific and more potent than dopamine in 
the renal vascular bed. Its vasodilating effects are selectively 
blocked by bulbocapnine and metoclopramide. The effects 
of fenoldopam are independent of alpha- and beta-adrenergic 
receptors, as well as cholinergic or histaminic receptors. 
This drug does not cause prostaglandin or endogenous cate•
cholamine release. In addition, administration of fenoldo•
pam does not significantly activate central dopaminergic 
receptors, indicating that it does not readily cross the blood•
brain barrier; thus, it might not cause nausea or vomiting, 
a problem with other dopaminergic compounds. It does not 
inhibit monoamine oxidase, but can inhibit norepinephrine 
uptake in vitro in concentrations greater than those necessary 
to dilate renal blood vessels. It has been given orally in 
patients with essential hypertension, lowering arterial blood 
pressure and reducing systemic and renal vascular resistance 
(7). 
Fenoldopam in heart failure. The present study sug•
gests that, at least acutely, oral administration of fenoldo-
I Hour 2 Hours 
97 ± 20 95 ± 18 
98 ± 13 97 ± 12 
97 ± 8 95 ± 10 
98 ± 11 96 ± 11 
98 ± 15 97 ± 15 
94 ± 10 95 ± 15 
86 ± 15* 87 ± 15* 
83 ± 8* 91 ± 12 
14 ± 8 14 ± 8 
12 ± 8 13 ± 7 
13 ± 6 13 ± 6 
13 ± 8 14 ± 8 
35 ± II 35 ± 12 
34 ± 7 34 ± 7 
30 ± 9* 30 ± 10 
29 ± 9 30 ± 9 
25 ± 9 26 ± 9 
23 ± 8 22 ± 7 
21 ± 8* 21 ± 7* 
20 ± 8* 22 ± 8 
3 Hours 
97 ± 16 
94 ± 15 
93 ± 13 
95 ± 10 
99 ± 17 
99 ± 14 
96 ± 13 
93 ± 9 
16 ± 8 
12 ± 8 
13 ± 8 
14 ± 8 
37 ± 6 
35 ± 4 
31 ± 10 
31 ± 10 
25 ± 6 
22 ± 8 
22 ± 7 
23 ± 7 
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4 Hours 
97 ± 16 
96 ± 13 
93 ± 10 
96 ± 11 
98 ± 15 
98 ± 15 
93 ± 13 
95 ± 15 
14 ± 8 
13 ± 6 
12 ± 7 
14 ± 9 
36 ± 12 
36 ± 8 
30 ± 11 
31 ± 10 
22 ± 7 
23 ± 8 
22 ± 6 
22 ± 7 
pam results in a significant reduction of arterial blood pres•
sure and subsequent augmentation of stroke volume without 
any significant change in heart rate. This suggests that 
impedance to left ventricular ejection is reduced. A modest 
decrease in mean pulmonary capillary wedge and mean pul•
monary artery pressures and no significant change in right 
atrial pressures were noted. The reduction in pulmonary 
wedge pressure without concomitant decrease in right atrial 
pressure probably reflects improvement in left ventricular 
dynamics rather than venodilation with subsequent preload 
reduction. Significant venodilation may not occur with this 
drug because of the reduced number of dopamine, receptors 
in the venous circulation (8). 
Previous studies with dopamine in patients with heart 
failure have shown that its beneficial actions are primarily 
due to positive inotropic effects mediated by beta,•
adrenergic receptors and, to a lesser degree, activation of 
dopamine receptors. This results in either a modest reduction 
or no change in the total peripheral resistance. This study 
shows, for the first time in patients with heart failure, re•
producible and significant reduction in systemic vascular 
resistance with concomitant increase in cardiac output by a 
drug that selectively stimulates vascular dopamine, recep•
tors only. If the vasodilatory effect of this drug is not subject 
to tachyphylaxis, potentially detrimental reactive hypertro•
phy may be prevented and symptoms ameliorated (9,10) 
during chronic administration. 
JACC Vol. 6, No.4 
October 1985:792-6 
Table 2. Derived Hemodynamic Effects of Fenoldopam 
Variable Baseline 30 Minutes 
Stroke volume index (mllm2) 
Placebo 24 :!:: 13 23 :!:: 13 
50 mg 25 :!:: 12 28 :!:: 12 
100 mg 22 :!:: 10 30 :!:: 13* 
200 mg 25 :!:: 16 33 :!:: 15* 
Cardiac index (liters/min per m2) 
Placebo 2.1 :!:: 0.8 2.0 :!:: 0.7 
50 mg 2.2 :!:: 0.7 2.6 :!:: 1.1 
100 mg 2.0 :!:: 0.8 2.8 :!:: 1.2* 
200 mg 2.2 :!:: 1.1 3.1 :!:: 1.3* 
Systemic vascular resistance 
(dynes.s.cm - 5) 
Placebo 1,983 :!:: 860 1,987 :!:: 850 
50 mg 1,730 :!:: 537 1,430 :!:: 473* 
100 mg 2,069 ± 815 1,335 :!:: 653* 
200 mg 1,987 :!:: 887 1,191 :!:: 559* 
Stroke work index (g_m1m2) 
Placebo 23 :!:: 13 23 :!:: 16 
50 mg 26 :!:: 20 28 :!:: 16 
100 mg 23 :!:: 16 28 :!:: 20 
200 mg 27 :!:: 24 30 :!:: 20 
*p < 0.05. 
Figure 1. Mean (± SEM) percent change from baseline of heart 
rate, pulmonary capillary wedge pressure, systemic vascular re•
sistance and cardiac index for the study group (n = 10) after 
placebo and 50, 100 and 200 mg fenoldopam dosing. 
50 
40 
30 
HEART RATE 
.PLACEB. 
0 50 • 0 
~100 
0200.0 
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1 Hour 2 Hours 3 Hours 4 Hours 
24 :!:: 13 24 :!:: 13 21 :!:: II 25 :!:: 12 
25 :!:: 13 24 :!:: 9 27 :!:: 16 23 :!:: II 
29 :!:: 13* 26 :!:: 11* 27 :!:: 14 26 :!:: 14 
30 :!:: 13* 30 :!:: 13* 26 :!:: 12 27 :!:: 14 
2.1 :!:: 0.7 2.1 :!:: 0.8 1.9 :!:: 0.9 2.3 :!:: 0.8 
2.3 :!:: 0.9 2.1 :!:: 0.7 2.2 :!:: 1.0 2.1 :!:: 0.8 
2.8 :!:: 1.1* 2.4 :!:: 0.8* 2.3 :!:: 0.9* 2.3 :!:: 0.9* 
2.8 :!:: 1.2* 2.7 :!:: 0.9* 2.4 :!:: 0.8 2.3 :!:: 0.9 
1,925 :!:: 627 1,861 :!:: 657 2,003 ± 833 1,721 ± 517 
1,681 :!:: 485 1,802 :!:: 653 1,897 :!:: 817 1,987 :!:: 912 
1,237 :!:: 352* 1,485 :!:: 496* 1,726 :!:: 602* 1,776 :!:: 620* 
1,205 :!:: 356* 1.366 :!:: 457* 1,628 :!:: 628 1,694 :!:: 520 
26 :!:: 19 25 :!:: 18 20 :!:: 12 27 :!:: 18 
26 :!:: 18 24 :!:: 11 29 :!:: 22 24 :!:: 13 
28 :!:: 20* 25 :!:: 17 28 :!:: 19* 26 ± 18* 
27 :!:: 16 29 :!:: 19 26 :!:: 17 27 :!:: 21 
Clinical implications of dopamine analogs. The de•
velopment of dopamine analogs that selectively stimulate 
dopamine I receptors is important because these receptors 
subserve smooth muscle relaxation in the renal (11-13), 
mesenteric (13-15), femoral, coronary (16,17) and cerebral 
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(18,19) vascular beds. This is in contradistinction to agents 
activating dopamine2 receptors, which are located on the 
postganglionic sympathic nerve terminal and may lead to 
an inhibition of norepinephrine release (20,21). These latter 
receptors are also present in the central nervous system and 
at ganglionic sites where they appear to reduce sympathetic 
tone. 
Fewer data are available regarding the use of selective 
dopamine analogs in congestive heart failure. We first re•
ported the hemodynamic effects of an n-dialkyl substituted 
dopamine analog, n-propyl-N-n-butyldopamine, in con•
scious dogs, normal human volunteers and patients with 
depressed ventricular function (22). This analog activates 
both dopaminel and dopamine2 receptors without beta•
adrenergic stimulation and little or no alpha-adrenergic vaso•
constrictor activity (23). In dogs, this analog lowered blood 
pressure without reflex tachycardia, increased renal blood 
flow and decreased renal vascular resistance. In normal hu•
man volunteers, renal blood flow was doubled with the 
administration of propylbutyldopamine and, in the subset 
of patients with heart failure, we found that increasing doses 
of this compound produced a steady and significant increase 
in cardiac index associated with a concomitant reduction in 
systemic vascular resistance without any significant changes 
in heart rate. Recently Francis et al. (24) reported the use 
of bromocryptine in 10 patients with congestive heart fail•
ure. This drug's pharmacologic actions appear to be me•
diated by stimulation of both dopaminel and dopamine2 
receptors. Their study suggested that, at least acutely, brom•
ocryptine improved the hemodynamic variables of these 
patients. 
Conclusions. The administration of oral fenoldopam re•
sulted in significant improvement of hemodynamic variables 
in patients with congestive heart failure. These effects seemed 
short-lived and primarily affected impedance to left ven•
tricular ejection. Further studies are needed to adequately 
assess the long-term effect of fenoldopam on the renal vas•
culature and heart failure in general. Fenoldopam's oral 
activity and potential for having few side effects may make 
it an attractive pharmacotherapeutic option in patients with 
severe heart failure. 
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